Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Neurodegeneration and Proteostasis

Neurodegeneration and Proteostasis

Friday, February 26, 2021, 8:30 AM - 6:00 PM EST

The New York Academy of Sciences

Presented By

The New York Academy of Sciences


Age-related neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease affect more than 7 million individuals and their families in the US alone. With an aging population worldwide, these diseases pose a significant economic and societal burden. With limited therapeutic options for Alzheimer’s disease in particular, there is an urgent need to identify new therapeutic opportunities for treating neurodegenerative diseases now.

The biological processes underlying proteostasis offer a new direction for development of innovative therapeutics. Within the last decade, the field of proteostatis biology has advanced considerably, notably with the 2016 Nobel Prize in Medicine awarded for work on autophagy.

Current efforts in academia and industry are now focused on developing the biology of proteostasis into useful medical treatments. Yet, the discourse between the proteostatis and neurodegeneration communities is currently insufficient to expedite translational breakthroughs.

This symposium will bring together experts in proteostasis biology and neurodegenerative disease, along with clinicians, drug developers, and investors to consider how to apply the emerging science of proteostasis to deliver transformational therapies for neurodegenerative disease.

Call for Abstracts

Abstract submissions are invited for a poster session. For complete submission instructions, please visit our online portal. The deadline for abstract submission is Friday, December 18, 2020.


Scientific Organizing Committee

Sonya Dougal, PhD

The New York Academy of Sciences

Jeffery Kelly , PhD

The Scripps Research Institute

Barbara Knappmeyer , PhD

The New York Academy of Sciences

Matthew Townsend, PhD

AbbVie Inc.


Ana Maria Cuervo MD, PhD

Albert Einstein College of Medicine

Fiona Elwood, PhD

Novartis Institutes for BioMedical Research

Steve Finkbeiner, MD, PhD

University of California, San Francisco

Jason Gestwicki, PhD

University of California, San Francisco

Katherine A. High

Spark Therapeutics Inc.

Peter T. Lansbury, PhD

Lysosomal Therapeutics, Inc.

Richard I. Morimoto, PhD

Northwestern University

Ralph A. Nixon, MD, PhD

Nathan S. Kline Institute

David Rubinsztein, PhD

University of Cambridge

Luke Wiseman, PhD

The Scripps Research Institute

Richard J. Youle, PhD

National Institute of Neurological Disorders and Stroke